Northwestern University researchers have developed the first device that can continuously track a fetus’s vital signs while still in the uterus.
For many women with early breast cancer, surgery is effective but life-altering. New five-year data from the National Institutes for Quantum Science and Technology (QST) suggest that a precisely targeted, high-energy particle therapy may allow some patients to avoid surgery without compromising oncologic outcomes.
mOm Incubators announced today that the FDA granted 510(k) clearance for its Essential Incubator system.
Johnson & Johnson (NYSE: JNJ)+
announced that it launched the Arbrea Breast Simulator Surgeon App for Mentor in the U.S.
Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies. TNBC is also more likely to metastasize, or travel through the bloodstream to spread to other organs, which causes most of breast cancer-related deaths each year.
BD (NYSE: BDX)+
announced today that the FDA granted 510(k) clearance for its EnCore EnCompass breast biopsy and tissue removal system.
IotaMotion announced today that it received FDA 510(k) clearance for expanded pediatric use of its iotaSoft insertion system.
A team of scientists from China has successfully created a miniature womb on a chip that mimics the complex environment of the human uterus. The research offers a new way to study the exact moment an embryo attaches to a mother’s body.
CMR Surgical announced today that it received CE mark and U.K. approval for its Versius surgical robot in pediatric surgery.
An evidence-based web-app helped children with epilepsy to fall asleep on average 16.5 minutes earlier.